Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 30 versus UROVIST CYSTO PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 30 versus UROVIST CYSTO PEDIATRIC.
CONRAY 30 vs UROVIST CYSTO PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is a water-soluble iodinated radiographic contrast agent that attenuates X-rays, providing vascular and organ opacification. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Radiopaque contrast agent that provides enhanced visualization of the urinary tract by attenuating X-rays due to its iodine content.
Intravenous: 50-300 mL of a 30% solution (150-900 mg iodine/kg) as a single dose for contrast enhancement. Dosing depends on procedure and patient weight.
Not applicable; Urovist Cysto Pediatric is a contrast agent for cystourethrography, instilled intravesically as a single dose of 5-10 mL for infants and 10-30 mL for children, not a systemic drug.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min)
After intravesical administration, systemic absorption is minimal; therefore, a meaningful terminal half-life is not defined. If absorbed, the elimination half-life of diatrizoate is approximately 1–2 hours in patients with normal renal function, reflecting rapid renal clearance.
Renal (90-100% unchanged via glomerular filtration within 24 hours); minimal biliary/fecal (<1%)
Urovist Cysto Pediatric (diatrizoate meglumine) is not significantly absorbed systemically after intravesical administration. The small fraction absorbed is excreted unchanged in urine via glomerular filtration, with 95% eliminated within 24 hours after intravenous administration; biliary/fecal excretion is negligible.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent